BioCentury | Apr 24, 2018
Distillery Therapeutics

Neurology

...include testing the compound in additional models of epilepsy. Novartis AG markets CAII inhibitor Azopt brinzolamide...
BioCentury | May 23, 2016
Strategy

Two heads are better

...as well as its ophthalmic drugs. The drugs included fixed-dose combinations Azarga brinzolamide/timolol and Simbrinza brinzolamide/brimonidine...
BioCentury | Apr 2, 2015
Distillery Therapeutics

Therapeutics: Carbonic anhydrase II (CAII); nitric oxide (NO)

...analog of the CAII inhibitor brinzolamide could help treat glaucoma by reducing intraocular pressure (IOP). Brinzolamide...
...production, whereas NO induces aqueous humor drainage. Chemical synthesis and in vitro testing of NO-donating brinzolamide...
...intraocular hypertension, topical application of the lead compound to the eye decreased IOP compared with brinzolamide...
BioCentury | Aug 11, 2014
Clinical News

Simbrinza brinzolamide/brimonidine tartrate regulatory update

...Novartis’ Alcon Inc. ophthalmic unit said the European Commission approved an MAA for Simbrinza brinzolamide/brimonidine tartrate...
...markets later this year and in 2015. The product is a fixed combination of 1% brinzolamide...
...ocular hypertension (see BioCentury, April 29, 2013). Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Product: Simbrinza brinzolamide/brimonidine...
BioCentury | Jun 9, 2014
Clinical News

Simbrinza brinzolamide/brimonidine tartrate regulatory update

...EMA's CHMP recommended approval of an MAA from Novartis' Alcon Inc. ophthalmic unit for Simbrinza brinzolamide/brimonidine...
...for whom monotherapy provides insufficient IOP reduction. The product is a fixed combination of 1% brinzolamide...
...ocular hypertension (see BioCentury, April 29, 2013). Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Product: Simbrinza brinzolamide/brimonidine...
BioCentury | Apr 29, 2013
Clinical News

Simbrinza brinzolamide/brimonidine tartrate regulatory update

...Novartis' Alcon Inc. ophthalmic unit said FDA approved Simbrinza brinzolamide/brimonidine tartrate to reduce intraocular pressure in...
...with primary open-angle glaucoma or ocular hypertension. The product is a fixed combination of 1% brinzolamide...
...that does not contain a beta blocker. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Product: Simbrinza brinzolamide/brimonidine...
BioCentury | Jul 30, 2012
Clinical News

Brinzolamide/brimonidine tartrate regulatory update

...earnings that its Alcon Inc. ophthalmic unit filed a regulatory application in the U.S. for brinzolamide/brimonidine...
...to treat intraocular pressure in patients with glaucoma. The product is a fixed combination of brinzolamide...
...indication that does not contain a beta blocker. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Product: Brinzolamide/brimonidine...
BioCentury | Dec 8, 2008
Clinical News

Azarga brinzolamide/timolol regulatory update

...Azarga in Europe early next year. Alcon Laboratories Inc. (NYSE:ACL), Fort Worth, Texas Product: Azarga brinzolamide/timolol...
BioCentury | Sep 29, 2008
Clinical News

Azarga brinzolamide/timolol regulatory update

...for whom monotherapy provides insufficient IOP reduction. Azarga is an eye drop combining 10 mg/mL brinzolamide...
...adrenoceptor beta1 and beta 2 antagonist. Alcon Laboratories Inc. (NYSE:ACL), Fort Worth, Texas Product: Azarga brinzolamide/timolol...
BioCentury | Apr 28, 2008
Clinical News

Azopt brinzolamide regulatory update

...EMEA's CHMP issued a positive opinion to extend the indication of Azopt brinzolamide ophthalmic solution to...
...inhibitor in the U.S. and EU. Alcon Laboratories Inc. (NYSE:ACL), Fort Worth, Texas Product: Azopt brinzolamide...
Items per page:
1 - 10 of 10